Drugs / SQ-HDM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT00389363 | Aug 2006 → Apr 2008 | asthma | ALK-Abelló A/S | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT01454544 | Oct 2011 → Apr 2013 | house allergic alveolitis | ALK-Abelló A/S | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2014-11-20 | ALK-Abelló A/S | Regulatory ALK submits registration application for house dust mite SLIT-tablet in Europe alk.net ↗
ALK's regulatory filing for the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the European health authorities via the Decentralised Procedure with Germany as the Reference Member State. |
| 2014-06-09 | ALK-Abelló A/S | Results ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen alk.net ↗
Today, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) has presented key trial results on its new sublingual allergy immunotherapy tablet (SLIT-tablet) for house dust mite (HDM) respiratory allergic diseases at the 2014 Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI), in Copenhagen, Denmark. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-11-20 | ALK-Abelló A/S | ALK submits registration application for house dust mite SLIT-tablet in Europe alk.net ↗ |
| 2014-06-09 | ALK-Abelló A/S | ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen alk.net ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SQ-HDM | “Six hundred four subjects at least 14 years old with HDM AR and mild to moderate HDM allergic asthma were randomized 1:1:1:1 to double-blinded daily treatment with 1, 3, 6...” PMID 25624131 ↗ Feb 20151“OBJECTIVE: To evaluate 12 SQ-HDM efficacy and safety across subgroups, and the onset, duration, and recurrence of local application site reactions.” PMID 29656145 ↗ Apr 2018 |
| Modality | Other / unclassified | “sublingual immunotherapy (SLIT)-tablet” PMID 29656145 ↗ Apr 2018 |